Clinical Trial Update: Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase III trial of PI-88 in post-resection hepatocellular carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• PI-88

Snippet

Sponsor: Progen Pharmaceuticals | Conditions: Cancer, Liver Cancer | Phase 3 | Status: TERMINATED